Longboard Pharmaceuticals Announces Steven W. Spector Joins the Company as General Counsel
November 02 2021 - 8:30AM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
Steven W. Spector, J.D., has joined the company as its General
Counsel.
"We are thrilled to have Steven formally join
Longboard at this time. Steven brings tremendous operational and
transactional expertise through all stages of drug development
spanning from early-stage research through commercialization as
well as across our therapeutic areas of focus," stated Kevin R.
Lind, Longboard’s President and Chief Executive Officer. "Steven
has been advising us since our inception and will continue to add
value as Longboard executes on its strategy. His passion for
advancing new therapies in neurological conditions strongly aligns
with our goal of making a difference for the patients and
communities we seek to serve."
Most recently, Mr. Spector has served as
part-time general counsel for several publicly traded companies,
including Longboard, Dynavax Technologies and Galecto, Inc. Prior
to this, Mr. Spector served as general counsel of Arena
Pharmaceuticals, Inc. for nearly twenty years, from October 2001 to
March 2020. He is a former President and long-time board of
director of the Association of Corporate Counsel, San Diego, and an
Adjunct Professor at the University of San Diego School of Law.
Prior to Arena, Mr. Spector was a partner with the international
law firm of Morgan Lewis, where he worked from 1991 to October
2001. Mr. Spector holds a B.A. and a J.D. from the University of
Pennsylvania. Mr. Spector and his family are active members in the
San Diego community, including supporting the ALS Association,
Sanford Burnham Prebys, and other non-profit organizations focused
on finding new approaches and treatments for rare neurological
conditions.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-hydroxytryptamine 2c receptor superagonist, with
negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes,
in development for the potential treatment of seizures associated
with developmental and epileptic encephalopathies. Longboard is
also evaluating LP143, a centrally acting, full cannabinoid type 2
receptor agonist, in development for the potential treatment of
neurodegenerative diseases associated with neuroinflammation caused
by microglial activation, and LP659, a centrally acting,
sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in
development for the potential treatment of central nervous system
neuroinflammatory diseases.
Forward-Looking
StatementsCertain statements in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements
about Longboard’s clinical and preclinical programs, ability to
develop medicines, focus, goal, and value. For such statements,
Longboard claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Longboard’s expectations. Factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements are disclosed in Longboard’s
filings with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024